Ibrance vs Pomalyst
Side-by-side drug price comparison from Medicare Part D data
Verdict
Ibrance costs 37% less per claim than Pomalyst ($10816.00 vs $17250.00). Ibrance has a generic alternative available. Total Medicare spending: Ibrance at $4.5B vs Pomalyst at $3.3B.
| Metric | Ibrance | Pomalyst |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $10,816* | $17,250 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $4.5B | $3.3B |
| Total Claims | 418,000 | 192,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -5.6%* | 4.7% |
| Generic Available | Yes | No |
| Condition | Cancer | Cancer |
| Total Beneficiaries | 36,000 | 18,000 |
Ibrance costs 37% less per claim than Pomalyst ($10816.00 vs $17250.00). Ibrance has a generic alternative available. Total Medicare spending: Ibrance at $4.5B vs Pomalyst at $3.3B.
Explore More
Comparing Ibrance and Pomalyst on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.